Modern clinical practice relies on evidence-based medicine (EBM) and evidence-based guidelines (EBGs). The critical evaluation of EBGs value is therefore an essential step to further improve clinical practice. In our opinion, correlating levels of evidence and grades of recommendation can be an easy tool to quickly display internal consistence of EBGs.
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Introduction
Evidence-based medicine (EBM) has been defined as the ''integration of best research evidence with clinical expertise and patient values''. The first historical descriptions of EBM date back to the beginning of 1990s, when the work of Gordon Guyatt, David Sackett and others established the emerging methodologies of EBM [8, 20] .
The main products of EBM are evidence-based guidelines (EBGs), ''systematically developed statements to assist practitioner and patient decision about appropriate health care for specific clinical circumstances'' [21] . EBGs indeed substantially improve clinical care [29] .
Costs, ethical concerns in placebo-controlled trials, publication bias and a real risk of reductionism are the most emphasized limitations of EBM. In order to overcome these limitations and improve EBGs quality standards, different societies (among which the World Health Organization, WHO) produced guidelines for guidelines developers.
Preliminary steps for guideline development are evaluation of priority settings [14] , composition of an expert panel [9] , management of conflicts of interests [3] , determination of appropriate group processes [10] , of important outcomes [22] and of which evidences have to be included [15] .
Then developers have to produce synthesis and presentation of evidences [16] , exposing criteria for grading evidence and recommendations [23] , integrating when possible values (e.g. ethical considerations) and consumer involvement [24] . Next, considerations of cost-effectiveness, affordability and resource implications [7] , of equity [17] , applicability, transferability and adaptation [25] should be included.
The final steps are the report of guidelines recommendations [18] , the dissemination and implementation of guidelines [11] and their evaluation [19] .
Since EBGs frequently vary widely in quality [26, 27] , their evaluation is very important. Updating a first systematic review [12, 28] found 24 different EBGs appraisal tools. The Appraisal of Guidelines for Research and Evaluation (AGREE) instrument was a validated, easy-to-use, and transparent tool, which was internationally developed and widely accepted. It was developed through a process of item generation, selection and scaling, field-testing and refinement. The final version of the instrument contained 23 items grouped into six domains: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence [2] .
Despite the good review of the AGREE instruments, two important limitations are present: although it can be used to compare clinical practice guidelines, AGREE instrument does not set a threshold to classify them as good or bad, and it does not assess the quality of the evidence supporting the recommendations [29] . Level of evidences and grade of recommendations in fact do not necessarily correlate, since the first is a measure of scientific strength and the latter of clinical utility.
Recently, an improved version of the AGREE, i.e. the AGREE II instrument, has been released [4, 5] , partly overcoming the previous limitations. Indeed, the introduction of the new item assessing the description of strengths and limitation of the body of evidences can be considered as a precursor for clinical validity or appropriateness of the recommendations. The authors recognize the value of this point, in fact they state that the AGREE consortium is targeting this area as its next priority for further study in the AGREE A3 initiative [6] . In our opinion, correlating level with grade could be a valid way to integrate the AGREE II instrument and quickly display the internal consistence of EBGs.
Material and methods
The guidelines for the treatment of bone metastases by the Italian Society for Medical Oncology (AIOM) are based on: European Society for Medical Oncology (ESMO) guidance on the use of bisphosphonates in solid tumors [1] and on the management of aromatase inhibitor-associated bone loss [13] ; Cochrane network reviews; critical review of the literature updated to June 2009.
The topics covered by the AIOM guidelines are use of bisphosphonates in metastatic cancers; use of bisphosphonates in the prevention and treatment of cancer treatment induced bone loss; safety of bisphosphonates use; treatment of bone metastases pain; role of bisphosphonates in specific settings; role of orthopedic surgery in bone metastases; role of radiotherapy in bone metastases. Level of evidences (I-VI) and grade of recommendations (A-E) were provided according to the recommendations of the Italian Centre for the Evaluation of the Efficacy of Health Assistance coordinated by the Italian National Health Institute (Istituto Superiore di Sanit a) and are presented in Table 1 .
We performed an analysis of levels of evidence and respective grades of recommendations of the guidelines for treatment of bone metastases by AIOM.
Spearman's rank correlation coefficient was calculated per each topic of the guidelines, a p value o0.05 was considered statistically significant. The final correlation was performed using a linear regression model (GraphPad Prims version 5.04, La Jolla California USA); linear r 2 value was reported to weight the results and a p value o0.05 was considered statistically significant.
Results
The results of our analysis showed a statistically significant correlation between the levels of evidence and the grades of recommendation in the following topics: use of bisphosphonates in metastatic cancers (p o0.01); use of bisphosphonates in the prevention and treatment of cancer treatment induced bone loss (p o0.01); safety of bisphosphonates use (po0.05); role of bisphosphonates in specific settings (p o0.01); role of orthopedic surgery in bone metastases (p o0.0001); role of radiotherapy in bone metastases (p o0.01).
Finally, a statistically significant correlation was also found considering all the levels of evidence and grades of recommendation together regardless of the division in topics (r 2 ¼ 0.4454, p o0.0001; Fig. 1 ).
Discussion
EBGs represent a milestone for modern evidence-based clinical practice; they indeed substantially improve clinical care [29] . Nevertheless, EBGs frequently vary widely in quality [26, 27] , thus their evaluation is of critical importance. Among several evaluation tools, the AGREE instrument is the most widely used, even though it has known limitations, i.e. the impossibility to classify EBGs as good or bad and to assess the quality of the evidences supporting the recommendations.
In order to overcome these limitations, we performed an analysis of levels of evidence and respective grades of recommendations of the guidelines for treatment of bone metastases by AIOM. In six out of seven topics, levels of evidence and respective grades of recommendations significantly correlated. Moreover, a statistically significant correlation was also found considering all the levels of evidence and grades of recommendation together regardless of the division in topics. These results indicate that the authors of the guidelines worked scientifically with a correct approach and that these guidelines are likely to be adherent with modern medical literature.
However, we cannot exclude that a significant correlation for some topics could be due to low levels of evidences from medical literature and consequent low grades of recommendations.
Moreover, the lack of concordance in specific items could also derive from the impossibility for the physicians to prescribe a specific drug in a specific setting (i.e. low grade of recommendation) due to the delayed approval by regulatory agencies (e.g. FDA, EMA) even in presence of adequate scientific literature (i.e. high level of evidence).
The critical evaluation of EBGs is an underestimated issue in current clinical practice. Moreover, specific methodological aspects for the evaluation of EBGs are of increasing interest in the medical oncology community. Here we provide clinicians with a quick tool to evaluate the internal consistence of EBGs. Further analysis should confirm the reliability of this method, which could be easily implemented in future EBGs. 
